Delivery Order SPE2DB22D3009-SPE2DB25FBE98
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for MULTAQ 400 MG tablets (60-count units) on June 16, 2025, with an ultimate completion date of June 17, 2025. This contract, valued at $9,756.31, utilizes firm fixed price terms and was awarded without a set-aside designation through competitive procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $3,736.64 to AmerisourceBergen Drug Corp for MULTAQ 400 mg tablets (60-count units) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price contract, which is not set-aside, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. MULTAQ (dronedarone) is an antiarrhythmic medication used to treat atrial fibrillation, reflecting the Defense Logistics...
- The Defense Logistics Agency awarded a $1,529.88 delivery order to AmerisourceBergen Drug Corp for MULTAQ 400 mg tablets (60-count packages) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The award was competitively procured with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $11,535.63 to AmerisourceBergen Drug Corp for 60 tablets of MULTAQ 400 mg on August 25, 2025, with a completion date of August 26, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being fulfilled from the vendor's location in Conshohocken, Pennsylvania. MULTAQ (dronedarone) is an antiarrhythmic medication used in the treatment of atrial fibrillation and represents one...
- The Defense Logistics Agency awarded a $1,890.09 delivery order to AmerisourceBergen Drug Corp for MULTAQ 400 mg tablets (60-count) under a firm fixed-price contract type. The award was issued on September 11, 2025, with an ultimate completion date of September 12, 2025. This delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. MULTAQ is a prescription antiarrhythmic medication used in the management...
- The Defense Logistics Agency awarded a $4,824.44 delivery order to AmerisourceBergen Drug Corp for MULTAQ 400 mg tablets (60 count) on September 3, 2025, with an ultimate completion date of September 4, 2025. This is a firm fixed-price, non-set-aside contract performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order represents a child contract action under the company's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for MULTAQ 400 MG tablets (60-count) valued at $6,160.39 under a firm fixed price contract type. The award was made on September 3, 2025, with an ultimate completion date of September 4, 2025. This non-set-aside competitive award will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. MULTAQ is a prescription antiarrhythmic medication used to reduce the risk...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of MULTAQ 400 MG tablets (60-count units) under a firm fixed-price contract valued at $2,583.97. This non-set-aside delivery order was awarded on August 26, 2025, with an ultimate completion date of August 27, 2025. Performance will occur at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of MULTAQ 400 mg tablets (60-count units) with a ceiling value of $11,894.31. This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded contract. The order is due for completion by September 10, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $11,072.34 to AmerisourceBergen Drug Corp for the supply of MULTAQ 400 mg tablets (60 count) on August 26, 2025, with an ultimate completion date of August 27, 2025. This is a firm fixed price contract with no set-aside designation, performed at the contractor's corporate office location in Conshohocken, Pennsylvania. MULTAQ is a prescription antiarrhythmic medication used to reduce the risk of cardiovascular hospitalization in...
- SPE2DB22D3009Indefinite Delivery Contract
- SPE2DB22D3009-SPE2DB25FBE98Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for MULTAQ 400 mg tablets (60-count units) under a firm fixed-price contract valued at $29,062.23. The delivery order, issued on September 12, 2025, carries an ultimate completion date of September 15, 2025, and represents a non-set-aside competitive award. Performance will occur at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, the company's headquarters location. This delivery order is a child contract under AmerisourceBergen's substantial indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. AmerisourceBergen, as a major pharmaceutical distributor, leverages this comprehensive global pharmaceutical support vehicle to supply medications and medical commodities to military healthcare programs and other federal agencies. MULTAQ (dronedarone) is an antiarrhythmic medication used in cardiac care, aligning with the company's extensive portfolio of specialty pharmaceuticals and demonstrating its capability to fulfill specialized medical procurement requirements for the Defense Health Agency and U.S. military healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $29.1k | 9/12/25 |